Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 18/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18254542 | 0.86 | APLNR (0.54) | APLNRPDE10AAVPR2AVPR1A | |
| SCHEMBL18246050 | 0.84 | APLNR (0.73) | APLNR | |
| SCHEMBL18247041 | 0.84 | APLNR (0.73) | APLNRPDE10AAVPR2AVPR1A | |
| SCHEMBL18246800 | 0.78 | APLNR (0.59) | APLNR | |
| SCHEMBL18254249 | 0.76 | APLNR (0.59) | APLNR | |
| SCHEMBL18254393 | 0.73 | APLNR (0.53) | APLNR | |
| SCHEMBL20189104 | 0.73 | APLNR (0.52) | APLNR | |
| SCHEMBL18247150 | 0.72 | APLNR (0.62) | APLNR | |
| SCHEMBL20187765 | 0.72 | APLNR (0.62) | APLNR | |
| SCHEMBL20189686 | 0.72 | APLNR (0.50) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751864-B2 | Methods for preparing triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751864-B2 | Methods for preparing triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170044131-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044131-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044131-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | APLNR 4/4885PDE10A 1447/4885AVPR2 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.